Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.
International Journal of Clinical Oncology|June 15, 2022
Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysisYusuke Ozeki, Naoya Kanogawa, Sadahisa Ogasawara, et al.
Case Reports in Oncology|December 11, 2023
Controlling Major Portal Vein Invasion Progression during Lenvatinib Treatment by Carbon-Ion Radiotherapy in Patients with Advanced Hepatocellular CarcinomaRyoi Yoshida, Keisuke Koroki, Hirokazu Makishima, et al.
BMJ Open|April 9, 2022
Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trialSadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima, et al.
Scientific Reports|March 6, 2021
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinomaHiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|November 24, 2021
Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironmentShohei Mukai, Hiroaki Kanzaki, Sadahisa Ogasawara, et al.
Nature Cancer|February 5, 2022
Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemiaMari Hashimoto, Yoriko Saito, Ryo Nakagawa, et al.
BMC Gastroenterology|March 11, 2023
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinomaNaoya Kanogawa, Sadahisa Ogasawara, Susumu Maruta, et al.
Scientific Reports|November 2, 2021
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinomaYuko Kusakabe, Tetsuhiro Chiba, Motohiko Oshima, et al.
Anticancer Research|February 28, 2023
Successful Identification of a Novel Therapeutic Compound for Hepatocellular Carcinoma Through Screening of ADAM9 InhibitorsKeita Ogawa, Tetsuhiro Chiba, Masato Nakamura, et al.
Pageof 9